Literature DB >> 30570871

MicroRNA-182 promoted esophageal squamous cell carcinoma cell growth and metastasis via targeting YWHAG.

Qizhou Bai1, Jun Yu, Yongshun Li, Jilong Ma, Yunjiu Gou.   

Abstract

PURPOSE: To study the functioning mode of miR-182 on esophageal squamous cell carcinoma (ESCC) cell growth and metastasis and provide therapeutic targets for ESCC.
METHODS: miR-182 expression level in ESCC cell lines was examined by quantitative real-time polymerase chain reaction (qRT-PCR). Using miR-182 inhibitor, we analyzed the effects of miR-182 down-expression on cell proliferation, invasion, cell apoptosis and cell cycle. Dual-luciferase activity assay was used to examine the potential target gene YWHAG which was predicted by several databases. Protein level was studied using western blotting.
RESULTS: Decreased expression of miR-182 in ESCC cells was accompanied by decreased cell invasion and proliferation, promotion of cell apoptosis and cell cycle arrest at G0/G1 phase. Dual-luciferase and western blot confirmed YWHAG as a target gene of miR-182. Furthermore, silence of YWHAG counteracted the suppressive effect of miR-182 down-expression on cell growth and metastasis.
CONCLUSIONS: miR-182 could suppress ESCC cell proliferation and metastasis via regulating YWHAG, which might provide a new target for ESCC diagnosis and therapy.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30570871

Source DB:  PubMed          Journal:  J BUON        ISSN: 1107-0625            Impact factor:   2.533


  2 in total

1.  Perversely expressed long noncoding RNAs can alter host response and viral proliferation in SARS-CoV-2 infection.

Authors:  Rafeed Rahman Turjya; Md Abdullah-Al-Kamran Khan; Abul Bashar Mir Md Khademul Islam
Journal:  Future Virol       Date:  2020-09       Impact factor: 1.831

2.  LOC441178 Overexpression Inhibits the Proliferation and Migration of Esophageal Carcinoma Cells via Methylation of miR-182.

Authors:  Weitao Hu; Zongchi Chen; Jiangmu Chen; Daxing Cai; Congjie Chen; Taiyong Fang
Journal:  Onco Targets Ther       Date:  2020-11-03       Impact factor: 4.147

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.